News for Healthier Living
ASH: Monoclonal Antibody Therapy Improves Survival in Cancer-Associated Hyper-Inflammatory Disorder
Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) - a rare, aggressive hyperinflammatory condition - who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.
December 9, 2024
December 21 2024December 20 2024December 19 2024December 18 2024December 17 2024December 16 2024December 15 2024December 14 2024December 13 2024December 12 2024December 11 2024December 10 2024December 9 2024December 8 2024December 7 2024
|
|
|
|
|